OnKure Therapeutics, Inc. OKUR
- OKI-345 — Breast Cancer Preclinical
- OKI-355 — Vascular Anomalies Preclinical
PI3Kα (3 companies · 5 programs)
Companies with an active program directed at PI3Kα.
Relay Therapeutics, Inc. RLAY
- zovegalisib — Breast Cancer Phase 3
- zovegalisib — PIK3CA-Related Overgrowth Spectrum Phase 2
Cogent Biosciences, Inc. COGT
- CGT6297 — Advanced Solid Tumors Phase 1